PMID- 22012040
OWN - NLM
STAT- MEDLINE
DCOM- 20120222
LR  - 20220629
IS  - 1980-5322 (Electronic)
IS  - 1807-5932 (Print)
IS  - 1807-5932 (Linking)
VI  - 66
IP  - 10
DP  - 2011
TI  - Plasma levels of procalcitonin and eight additional inflammatory molecules in 
      febrile neutropenic patients.
PG  - 1699-705
AB  - OBJECTIVE: This study aimed to examine the association between different 
      inflammatory markers and specific clinical endpoints in patients with febrile 
      neutropenia. METHOD: We prospectively evaluated the expression of procalcitonin 
      (PCT), interleukin 8 (IL-8), induced protein-10, tumor necrosis factor alpha 
      (TNF-alpha), two soluble TNF-alpha receptors (sTNF-R I and sTNF-R II), monocyte 
      chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha, and 
      eotaxin in 37 episodes of febrile neutropenia occurring in 31 hospitalized adult 
      onco-hematologic patients. Peripheral blood samples were collected in the morning 
      at inclusion (day of fever onset) and on days 1, 3, and 7 after the onset of 
      fever. Approximately 2-3 ml of plasma was obtained from each blood sample and 
      stored at -80  degrees C. RESULTS: The sTNF-R II level at inclusion (day 1), the PCT 
      level on the day of fever onset, and the change (day 3 - day 1) in the IL-8 and 
      eotaxin levels were significantly higher in patients who died during the 28-day 
      follow-up. A requirement for early adjustment of antimicrobial treatment was 
      associated with higher day 3 levels of IL-8, sTNF-R II, PCT, and MCP-1. 
      CONCLUSION: Procalcitonin, sTNF-R II, IL-8, MCP-1, and eotaxin could potentially 
      be used to assess the risk of death and the requirement for early adjustment of 
      antimicrobial treatment in febrile, neutropenic onco-hematologic patients. The 
      levels of the other markers showed no association with any of the evaluated 
      endpoints.
FAU - Neuenschwander, Leticia Carvalho
AU  - Neuenschwander LC
AD  - Postgraduate Course in Infectious Diseases and Tropical Medicine, Internal 
      Medicine Department, School of Medicine, Universidade Federal de Minas Gerais, 
      Belo Horizonte/MG, Brazil.
FAU - Bittencourt, Henrique
AU  - Bittencourt H
FAU - Ribeiro, Ana Flavia Tiburcio
AU  - Ribeiro AF
FAU - Teixeira, Antonio Lucio
AU  - Teixeira AL
FAU - Teixeira, Mauro M
AU  - Teixeira MM
FAU - Teixeira, Jairo Cerqueira
AU  - Teixeira JC
FAU - Nobre, Vandack
AU  - Nobre V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clinics (Sao Paulo)
JT  - Clinics (Sao Paulo, Brazil)
JID - 101244734
RN  - 0 (Biomarkers)
RN  - 0 (CALCA protein, human)
RN  - 0 (Chemokine CCL11)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL3)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Protein Precursors)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (TNFRSF1A protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-12-9 (Calcitonin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Calcitonin/*blood
MH  - Calcitonin Gene-Related Peptide
MH  - Cause of Death
MH  - Chemokine CCL11/blood
MH  - Chemokine CCL2/blood
MH  - Chemokine CCL3/blood
MH  - Epidemiologic Methods
MH  - Female
MH  - Humans
MH  - Inflammation/blood
MH  - Interleukin-6/blood
MH  - Interleukin-8/blood
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/*blood/mortality
MH  - Prospective Studies
MH  - Protein Precursors/*blood
MH  - Receptors, Tumor Necrosis Factor, Type I/blood
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/blood
PMC - PMC3180156
COIS- No potential conflict of interest was reported.
EDAT- 2011/10/21 06:00
MHDA- 2012/02/23 06:00
PMCR- 2011/10/01
CRDT- 2011/10/21 06:00
PHST- 2011/04/23 00:00 [received]
PHST- 2011/06/19 00:00 [accepted]
PHST- 2011/10/21 06:00 [entrez]
PHST- 2011/10/21 06:00 [pubmed]
PHST- 2012/02/23 06:00 [medline]
PHST- 2011/10/01 00:00 [pmc-release]
AID - S1807-5932(22)02325-0 [pii]
AID - cln_66p1699 [pii]
AID - 10.1590/s1807-59322011001000006 [doi]
PST - ppublish
SO  - Clinics (Sao Paulo). 2011;66(10):1699-705. doi: 10.1590/s1807-59322011001000006.